Characteristics and transplant outcome of myeloid sarcoma: a single-institute study
- 28 January 2021
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 113 (5) , 682-692
Abstract
We performed a retrospective study describing the characteristics of myeloid sarcoma (MS) and evaluated the outcome of hematopoietic stem cell transplantation (HSCT) in patients with MS. There were 27 patients with de novo isolated MS, 34 with de novo leukemic MS and 13 with secondary leukemic MS in our study. Sixty-three patients received induction chemotherapy. Following induction therapy, 35 patients underwent HSCT, including 10 autogenous HSCT (auto-HSCT) and 25 allogeneic HSCT (allo-HSCT) cases. Compared with intensive chemotherapy only as consolidation treatment, HSCT (auto-/allo-HSCT) significantly improved the overall survival (OS) of MS patients (p < 0.05), while allo-HSCT also improved progression-free survival (PFS, p = 0.032). According to multivariate analysis, poorer prognosis in terms of OS was observed in older patients (p = 0.024, HR = 1.030, 95% CI 1.004–1.057), while HSCT (auto/allo-HSCT) had a favorable impact on OS for patients with MS (auto-HSCT, p = 0.044, HR = 0.201, 95% CI 0.042–0.959; allo-HSCT, p = 0.038, HR = 0.341, 95% CI 0.124–0.943). Extramedullary disease without complete remission (CR) after induction therapy was the sole variable independent of high OS and PFS (p = 0.049, HR = 2.243, 95% CI: 1.005–5.005; p = 0.017, HR = 2.535, 95% CI 1.180–5.448, respectively). The data indicate that HSCT is an effective treatment for patients with MS who have achieved CR of extramedullary disease after induction therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81730003, 81870120)
- Natural Science Foundation of Jiangsu Province (BK20171205)
- Social development project of Jiangsu province (BE2019655)
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- National key research and development program (2017ZX09304021, 2017YFA0104500, 2019YFC0840604)
This publication has 30 references indexed in Scilit:
- Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcomaLeukemia, 2012
- How I treat extramedullary acute myeloid leukemiaBlood, 2011
- Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow TransplantationHaematologica, 2011
- Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TCJournal of Clinical Oncology, 2008
- Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemiaCancer, 2008
- Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patientsLeukemia, 2006
- Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation culturesBlood, 2006
- Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapyLeukemia, 2003
- Comparison in treatments of nonleukemic granulocytic sarcomaCancer, 2002
- Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant DataJournal of the American Statistical Association, 1974